Iman Osman

NYU Langone Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Phenotypic plasticity is a prominent cancer feature that contributes to metastatic potential and resistance to therapy across multiple cancer types. Cancer cell state transitions have been attributed to transcriptional programs, such as the AP1/TEAD-regulated gene network driving the mesenchymal-like (MES) phenotype. In addition, during dissemination, tumor cells are subjected to variable loads of physical mechanical pressure and constriction across transited tissue, which are thought to impact nuclear molecular crowding. How the interplay between mechanical pressure, global 3D nuclear architecture and transcriptional programs contributes to MES identity and metastatic adaptation remains unclear. Using cutaneous melanoma as a model for early dissemination, we integrate in vitro and in vivo epigenomic profiling with nanoscale imaging of cell lines and patient samples to investigate chromatin organization features underlying the MES phenotype. We find that in MES cells, CTCF is relocated from domain boundaries to regulatory regions of EMT-like genes, leading to reduced insulation, extended topological associated domains (TADs) and increased inter-domain contacts, and de novo formation of chromatin hubs. This conformational rewiring, along with loss of heterochromatin, supports nuclear deformability during invasion and dissemination. Conversely, physical constriction of melanocytic cells induces MES-like chromatin features —including CTCF repositioning and heterochromatin loss— and promotes metastasis in vivo. Similarly, pharmacological inhibition of the heterochromatin mark H3K9me3 triggers MES characteristics and increases invasiveness. These results demonstrate that metastatic competency involves both epigenetic and structural nuclear reprogramming, enabling shifts in gene networks and physical adaptability. Our findings reveal mechanistic links between nuclear architecture and aggressive tumor behavior, identifying potential biomarkers and therapeutic targets to intercept metastatic progression.

Year:

2026

Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.

Year:

2025

Targeted therapies and immunotherapy have improved treatment outcomes for many patients with melanoma. However, patients whose melanomas harbor driver mutations in the neurofibromin 1 ( NF1 ) tumor suppressor gene often lack effective targeted treatment options when their tumors do not respond to immunotherapy. In this study, we utilized patient-derived short-term cultures and multiomics approaches to identify molecular features that could inform the development of therapies for patients with NF1 -mutant ( NF1 Mut ) melanoma. Differential gene expression analysis revealed that EGFR is highly expressed and active in NF1 Mut melanoma cells, in which it hyperactivates ERK and AKT, leading to increased tumor cell proliferation, survival, and growth. In contrast, genetic or pharmacologic inhibition of EGFR hindered cell proliferation and survival and suppressed tumor growth in patient-derived NF1 Mut melanoma models but not in NF1 wild-type models. These results reveal a connection between NF1 loss and increased EGFR expression that is critical for the survival and growth of NF1 Mut melanoma cells in patient-derived culture and xenograft models, irrespective of their BRAF and NRAS mutation status. Significance: NF1 mutant melanomas rely on EGFR activation and can be effectively treated with the EGFR inhibitors cetuximab or afatinib, supporting further testing in clinical trials.

Year:

2025

Purpose: Cancer treatment has been revolutionized by immune checkpoint inhibitors (ICI). However, a subset of patients do not respond and/or they experience significant adverse events. Attempts to integrate reliable biomarkers of ICI response as part of standard care have been hampered by limited generalizability. We previously reported our supervised machine learning (ML) model in a retrospective cohort of metastatic melanoma. Experimental Design: In this study, we expanded our testing to include larger cohorts of patients with melanoma accrued at several sites, including patients enrolled in clinical trials in both adjuvant and metastatic settings. We examined pretreatment hematoxylin and eosin slides from 639 patients with stage III/IV melanoma treated with ICIs [anti–cytotoxic T-lymphocyte–associated protein 4 ( n = 212), anti-programmed death 1 ( n = 271), or the combination ( n = 156)]. We tested the generalizability of our supervised ML algorithm to predict response to ICIs in the metastatic melanoma cohort and then developed a self-supervised ML model to identify the histologic morphologies associated with patients’ survival following ICI use in adjuvant and metastatic melanoma cohorts. Results: We predicted the response to ICI treatment with an AUC of 0.72. The deep convolutional neural network classified patients into high and low risk based on their likelihood of progression-free survival ( P Conclusions: Our data support the generalizability of our developed ML algorithm in predicting response to ICI treatment in patients with metastatic unresectable melanoma. We also showed, for the first time, tumor features associated with patients’ overall survival.

Year:

2025

CRISPRi screen for overexpressed lncRNAs in melanoma pathogenesis and expression of selected hits. A, Graphical outline of the conducted CRISPRi screen in the 501mel cell line. MOI, multiplicity of infection. B, Principal component analysis plot of samples used for the CRISPRi screen. D8 and D12 refer to selected 501mel-dCas9-KRAB single-cell clone and D7, D14. and D21 for the days of screening time. Negative control refers to no Dox treatment, and the plasmid library for lentivirus production was added as additional control. PC, principal component. C, Dot plots show results of the CRISPRi lncRNA library screen at time points day 7, 14, and 21 after selection and mCherry + /GFP + cells sort as CPM of control (= day 0) vs. respective time points. Each dot represents a single sgRNA. Red dots indicate significantly depleted sgRNAs and log 2 fc > −1. D, List showing top 10 depleted lncRNA (excluding PVT1 as not validated after screen) hits at day 21 vs. control day 0 as the mean log 2 fc of the top three depleted sgRNAs of each respective lncRNA. E, CRISPRi hit validation of top 2 to 3 individual sgRNAs of indicated lncRNAs; top: GFP competition assay in 501mel-dCas9-KRAB from days 4 to 24 by flow cytometry in percent GFP-positive cells. sgROSA (black curve) serves as a negative control. Curves show average GFP signal loss of sgRNAs shown in bottom: bar graphs of fold change GFP expression of individual sgRNAs relative to control at day 24. For color codes, see top panel. F, Boxplot showing the log 2 CPM expression of selected lncRNA CRISPRi screening hits RP11-267N12.3, RP11-120D5.1, BDNF-AS, XLOC_030781, and GMDS-AS1 in melanocytes ( n = 4), brain metastasis ( n = 5), and LN STCs ( n = 4) detected by RNA-seq. Ctrl, control; Mets, metastasis.

Year:

2025

TCGA XLOC_030781 expression data analysis in cancer and clinical melanoma samples. A, Pan-cancer expression analysis using TCGA. SKCM, skin cutaneous melanoma. B, UCSC genome browser snap shots of H3K27ac ChIP-seq data from melanoma (MM, black), non-malignant skin biopsies (NHM, black), foreskin sample (green), and other malignant samples (other colors) at the XLOC_030781/ENSG00000287723 locus. Pink bar shows the peak area of interest in the vicinity of XLOC_030781 promoter. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse Large B-cell Lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney Chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, low grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.

Year:

2025

XLOC_030781 CRISPRi knockdown and RNA-seq transcriptomic expression analysis in 501mel-dCas9-KRAB. A, Principal component analysis (PCA) of sgXLOC_030781 CRISPRi at days 3 and 5 after infection vs. day 0 negative control ( n = 2). B, Volcano plot of significantly differentially expressed genes (red) upon sgXLOC_030781 knockdown at day 3; P value cutoff = 0.05 and log 2 fc = 1. C, GO enrichment analysis of up- and downregulated gene sets upon sgXLOC_030781 knockdown at day 3. D, GSEA enrichment analysis of each top example of upregulated (ER to Golgi vesicle transport, left) and downregulated genes (DNA replication–dependent nucleosome assembly, right). E, Upstream TF analysis of up- and downregulated genes using ChEA upon sgXLOC_030781 knockdown at day 3.

Year:

2025

CRISPRi screen lncRNA hit functional characterization. A, Flow cytometry–based dotmplot showing GFP and mCherry signal as proxy for sgRNA and dCas9 expression (left). 7-AAD fluorescence–dependent cell cycle analysis in 501mel-dCas9-KRAB (top) and WM136a-dCas9-KRAB (bottom) cell lines upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 CRISPRi knockdown (rigth). Note that the top panel is plotted linear and bottom logarithmic because of better cell cycle–gating parameters. B, Cell cycle phase quantification based on A in percent of cells ( n = 2). C, PARP cleavage apoptosis assay performed by Western blotting upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 knockdown in 501meld-Cas9-KRAB and WM1361a-dCas9-KRAB Representative Western blots (top). GAPDH detection was used as a loading control; densitometric quantification of apoptosis as cleaved PARP/GAPDH protein ratio (bottom; average of n = 2). sgROSA served as negative control and etoposide apoptosis inducer as positive control. D, Re-analysis of 7-AAD cell cycle assay staining using exact same gating parameters for sub-G 1 cellular fraction indicative of apoptosis. E, Transwell cell migration assay. Fluorescence photomicrographs show calcein-stained migrated cells of sgBDNF-AS, sgGMDS-AS1, and sgXLOC_030781 knocked-down 501mel-dCas9-KRAB cells vs. sgROSA negative control and quantification of average sum count cell numbers ( n = 2).

Year:

2025

LncRNA candidate selection for CRISPRi screen and expression of lncRNAs associated to melanomagenesis. A, Flow diagram of integrated RNA- and ChIP-seq for the preselection of lncRNAs. Selection parameters are FDR 0.75, and CPM > 1 in higher expressed cell type, either histone mark (H3K4me3 or H3K27ac) in the higher expressed cell type; no mono-exonic lncRNAs and log fc ≥ 0.5 between investigated cell type and either WM1361a or 501mel. B, Heatmap of differentially expressed lncRNAs by RNA-seq in patient/donor-derived melanocytes ( n = 4) and metastatic STCs (BM, brain metastasis, n = 5; LN, lymph node metastasis, n = 4) and melanoma cell lines 501mel ( n = 4) and WM1361a ( n = 3). C, Heatmap showing differential lncRNA expression in the SK-Mel239 parental melanoma cell line versus BRAF and 1059 MEKi-resistant cell line ( n = 2). D, Boxplot showing the log 2 CPM expression of selected melanoma-associated lncRNAs SAMMSON, MEG3, H19, and PCAT1 in melanocytes ( n = 4), brain metastasis ( n = 5), and LN STCs ( n = 4) detected by RNA-seq. DE, differentially expressed; Mets, metastasis; TSS, transcription start site.

Year:

2025

Melanoma being one of the most common and deadliest skin cancers has been increasing since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays, the standard of care of advanced melanoma is resection, followed by immune checkpoint inhibition–based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistance. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long noncoding RNAs (lncRNA) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistance; however, systematic screens to uncover novel functional lncRNAs are scarce. In this study, we profile differentially expressed lncRNAs in patient-derived short-term metastatic cultures and BRAF–MEK inhibition–resistant cells. We conduct a focused growth-related CRISPR inhibition screen of overexpressed lncRNAs, validate, and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities, and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance in melanoma. Significance: LncRNAs have emerged as novel players in regulating many cellular aspects also in melanoma. The number of functional significances of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR inhibition growths screens. Our results broaden the characterized lncRNAs as potential targets for future therapeutic applications.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (39)

Palaniraja Thandapani

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Leah Morales

NYU Langone Medical Center

UNITED STATES
View details

Yuting Lu

New York University

UNITED STATES
View details

Graham Mann

Professor

University of Sydney

AUSTRALIA
View details

Adam Reynolds

Research Assistant Professor

University of New Mexico

UNITED STATES
View details

Shaofeng Yan

-

UNITED STATES
View details

Yongzhao Shao

New York University Grossman School of Medicine

UNITED STATES
View details

Cheryl Thompson

Professor and Associate Director for Population Sciences, Penn State Cancer Institute

Pennsylvania State University

UNITED STATES
View details

Aristotelis Tsirigos

Associate Professor (Research) of Pathology

NYU School of Medicine

UNITED STATES
View details

Christopher I. Amos

Associate Director for Population and Data Science

Baylor College of Medicine

UNITED STATES
View details

George Jour

Associate professor

NYU Langone Medical Center

UNITED STATES
View details

Ke Yuan

Reader

University of Glasgow

UNITED KINGDOM
View details

Markus Schober

Associate Professor

NYU Langone Health

UNITED STATES
View details

Pauline Funchain

Stanford University

UNITED STATES
View details

Marcus Bosenberg

Professor

Yale University

UNITED STATES
View details

Marianne Berwick

Professor

University of New Mexico

UNITED STATES
View details

David Ollila

Professor of Surgery

University of North Carolina at Chapel Hill

UNITED STATES
View details

Marc Ernstoff

Chief

National Institutes of Health

UNITED STATES
View details

Amanda Lund

NYU Langone Health

UNITED STATES
View details

Anne E Cust

Deputy Director, The Daffodil Centre

University of Sydney

AUSTRALIA
View details

Ata Moshiri

Associate Professor

NYU School of Medicine

UNITED STATES
View details

Eric Wang

Assistant Professor

Jackson Laboratory - Farmington

UNITED STATES
View details

Jane Skok

PI

NYU School of Medicine

UNITED STATES
View details

Kelly Ruggles

Associate Professor

NYU School of Medicine

UNITED STATES
View details

David Polsky

Alfred W. Kopf, M.D. Professor of Dermatologic Oncology and Professor (Clinical) of Pathology (Academic)

NYU School of Medicine

UNITED STATES
View details

Tim Lee

The University of British Columbia

UNITED STATES
View details

Pei-Fen Kuan

Professor

Stony Brook University

UNITED STATES
View details

Paul Googe

Professor and Laboratory Director

University of North Carolina at Chapel Hill

UNITED STATES
View details

James Wilmott

Associate Professor

The University of Sydney Library

AUSTRALIA
View details

Eva Hernando

Professor

NYU Langone Medical Center

UNITED STATES
View details

Jiahan xiong

NYU Langone Health

UNITED STATES
View details

Douglas B. Johnson

Vanderbilt University Medical Center

UNITED STATES
View details

Sheri L. Holmen

Professor

University of Utah Health Sciences Center

UNITED STATES
View details

Carla Daniela Robles-Espinoza

Group Leader

National Autonomous University of Mexico

View details

Tomas Kirchhoff

Assistant Professor of Population Health and Environmental Medicine

NYU School of Medicine

UNITED STATES
View details

Richard A. Scolyer

Faculty Member

University of Sydney

AUSTRALIA
View details

David Rimm

Professor

Yale University

UNITED STATES
View details

E. Nagore

Profesor Asociado

Universidad Católica de Valencia San Vicente Mártir Facultad de Medicina Facultad de Medicina y Odontología

SPAIN
View details

David Corcoran

Assistant Professor

University of North Carolina

UNITED STATES
View details